Health

In a relentless wave of tragedy, ophthalmologist Elias Jaradeh finds himself entrenched in a nightmare scenario that no medical professional should have to confront. For nearly a week, he has been tirelessly operating on a deluge of patients—a catastrophic situation fueled by the explosion of numerous handheld communication devices across Lebanon. While the main culprits
0 Comments
Recent findings from French registry data have underscored a stark and concerning trend: women with relapsing multiple sclerosis (MS) are significantly less likely to receive treatment compared to their male counterparts. This alarming contrast raises critical issues about gender bias in medical treatment paradigms, particularly in the context of chronic illnesses like MS. The study
0 Comments
The Federal Trade Commission (FTC) has taken a significant step by filing a lawsuit against three dominant pharmacy benefit managers (PBMs), namely Caremark, Express Scripts, and OptumRx. This lawsuit sheds light on the controversial role these entities play in the skyrocketing costs of essential medications, particularly insulin, which is vital for millions of Americans living
0 Comments
The intersection of politics and public health remains a deeply complex and contentious issue in the United States. As debates heighten surrounding the role of governmental figures like Robert F. Kennedy Jr., particularly in relation to public health leadership within a potential Trump administration, the implications for health policy and vaccine confidence become exceedingly pertinent.
0 Comments
In recent years, coffee has transcended its role as a mere beverage, emerging as a subject of scientific scrutiny due to its potential health benefits. A study published in the Journal of Clinical Endocrinology & Metabolism has revealed a noteworthy correlation between moderate coffee consumption—roughly 200-300 mg of caffeine daily—and a reduced risk of cardiometabolic
0 Comments
The recent endorsement by the Food and Drug Administration (FDA) of ribociclib, marketed as Kisqali, marks a significant progression in the treatment of early high-risk breast cancer. Specifically approved for use in conjunction with endocrine therapy as an adjuvant treatment, this new indication broadens the therapeutic landscape for patients diagnosed with hormone receptor-positive and human
0 Comments
Muscle-invasive bladder cancer (MIBC) presents a significant clinical challenge due to its high recurrence rate and bleak prognosis following standard treatments. Traditionally, neoadjuvant chemotherapy has aimed to improve overall survival rates by reducing tumor sizes before surgical intervention. A recent phase III trial, known as NIAGARA, marked a pivotal moment in this landscape by demonstrating
0 Comments
Recent advancements in the realm of oncology have highlighted the potential of combining retifanlimab (marketed as Zynyz) with standard chemotherapy to enhance treatment outcomes for patients suffering from locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). Results from a phase III clinical trial have underscored the improved progression-free survival (PFS) associated
0 Comments
In recent years, there has been a growing interest in the relationship between hormone therapy (HT) and insulin resistance, particularly in healthy postmenopausal women. A systematic review and meta-analysis encompassing 23 randomized trials have shed light on this topic, indicating that hormone therapy may significantly reduce insulin resistance, a condition linked to various metabolic disorders.
0 Comments